Jushi Holdings Applies for DEA Registration of Medical Operations

First-Mover Registration Strategy

Jushi filed DEA registration applications for medical dispensaries across seven states where it holds active licenses. The company disclosed the applications in a securities filing but didn't specify which facilities or state programs were included. DEA registration isn't currently required for state-licensed cannabis operators, but the agency's proposed rescheduling rule would mandate federal registration for any entity handling Schedule III controlled substances.

The filing puts Jushi ahead of most competitors. Only a handful of MSOs have publicly disclosed DEA registration applications, despite the rescheduling proposal entering its tenth month of administrative review.

Rescheduling Timeline and Regulatory Uncertainty

The DEA hasn't finalized its rescheduling decision, leaving cannabis operators in limbo on federal compliance requirements. The agency's Notice of Proposed Rulemaking, published in August 2023, outlined a pathway to move cannabis from Schedule I to Schedule III under the Controlled Substances Act. That change would subject cannabis businesses to DEA oversight — facility inspections, inventory audits, quarterly reporting.

No effective date has been announced. The DEA's administrative law judge hearings concluded in March 2026, but the final rule hasn't been published in the Federal Register. Industry attorneys estimate a Q3 or Q4 2026 implementation if the rule advances without further delay.

Operational and Compliance Implications

DEA registration requires facility-level applications, background checks on key personnel, and ongoing compliance with federal recordkeeping standards. Each dispensary, cultivation site, and processing facility must register separately. Registration fees range from $731 to $3,047 per site depending on the registration class, according to DEA fee schedules.

Jushi operates 33 dispensaries and 11 cultivation or processing facilities across Pennsylvania, Virginia, Illinois, Massachusetts, Ohio, Nevada, and California. If all facilities require registration, the company faces upfront costs exceeding $130,000 in application fees alone. That excludes legal and compliance consulting expenses. The company hasn't disclosed whether it filed applications for cultivation and processing sites or only patient-facing retail locations.

Competitive Positioning and Market Reaction

Jushi's proactive filing may accelerate a wave of DEA applications from competitors seeking to avoid operational disruption if rescheduling takes effect. Curaleaf, Trulieve, and Green Thumb Industries haven't publicly disclosed DEA registration filings as of May 2026, according to securities filings reviewed by CannIntel.

It also signals confidence that rescheduling will proceed despite political headwinds. The proposal has drawn opposition from Republican lawmakers and some public health groups, who argue that Schedule III placement undermines the FDA approval process for pharmaceuticals.

For full background on this regulatory shift, see the CannIntel topic hub on DEA registration for cannabis operators.

What Operators Should Watch

The DEA hasn't issued public guidance on the registration application process for cannabis businesses under a Schedule III framework. Existing DEA registration procedures apply to pharmaceutical manufacturers, distributors, and researchers handling controlled substances. But the agency hasn't clarified whether cannabis operators will follow identical protocols or a modified pathway.

Key variables include whether the DEA will grandfather existing state licenses, require separate federal inspections before approval, or impose additional security and inventory controls beyond state requirements. Operators waiting for clarity risk a bottleneck. If thousands of applications flood the agency after a final rule is published, delays are inevitable.